Compare BOC & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOC | ORGO |
|---|---|---|
| Founded | 2009 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.5M | 348.6M |
| IPO Year | 2010 | 2016 |
| Metric | BOC | ORGO |
|---|---|---|
| Price | $13.30 | $2.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 271.2K | ★ 1.1M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1600.00 |
| EPS | ★ N/A | N/A |
| Revenue | $114,376,348.00 | ★ $564,169,000.00 |
| Revenue This Year | $5.79 | N/A |
| Revenue Next Year | $4.76 | $26.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 5.64 | ★ 17.04 |
| 52 Week Low | $10.52 | $2.04 |
| 52 Week High | $14.50 | $7.08 |
| Indicator | BOC | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 60.11 | 42.23 |
| Support Level | $11.95 | $2.26 |
| Resistance Level | $13.93 | $2.67 |
| Average True Range (ATR) | 0.55 | 0.15 |
| MACD | 0.16 | -0.03 |
| Stochastic Oscillator | 83.69 | 23.97 |
Boston Omaha Corp is a diversified holding company engaged in outdoor billboard advertising, broadband services, surety insurance, and related brokerage activities, and asset management. The company generates revenue mainly from leasing advertising space on billboards, providing broadband internet services, and earning premiums and commissions from its insurance operations. In addition, it holds minority equity investments in various businesses, including real estate-related and other industries.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.